These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28033514)

  • 21. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
    Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence.
    van Kraaij MG; Verdonck LF; Rozenberg-Arska M; Dekker AW
    Bone Marrow Transplant; 2002 Sep; 30(5):303-9. PubMed ID: 12209352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation.
    Torda A; Chong Q; Lee A; Chen S; Dodds A; Greenwood M; Larsen S; Gilroy N
    Transpl Infect Dis; 2014 Oct; 16(5):751-9. PubMed ID: 25040633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large-scale multiplex polymerase chain reaction assay for diagnosis of viral reactivations after allogeneic hematopoietic stem cell transplantation.
    Inazawa N; Hori T; Hatakeyama N; Yamamoto M; Yoto Y; Nojima M; Suzuki N; Shimizu N; Tsutsumi H
    J Med Virol; 2015 Aug; 87(8):1427-35. PubMed ID: 25946433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quantitative real-time PCR--usefulness in detection and monitoring of CMV infection after hematopeietic stem cells transplant].
    Grabarczyk P; Brojer E; Nasiłowska B; Mariańska B
    Pol Merkur Lekarski; 2006 Sep; 21(123):227-31. PubMed ID: 17163182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of age and gender with alphaherpesvirus infections of the central nervous system in the immunocompetent host.
    Puchhammer-Stöckl E; Aberle SW; Heinzl H
    J Clin Virol; 2012 Apr; 53(4):356-9. PubMed ID: 22265826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders.
    Yamane A; Mori T; Suzuki S; Mihara A; Yamazaki R; Aisa Y; Nakazato T; Shimizu T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):100-6. PubMed ID: 17222758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation.
    Hubmann M; Fritsch S; Zoellner AK; Prevalsek D; Engel N; Bücklein V; Mumm F; Schulz C; Stemmler HJ; Jäger G; Ledderose G; Kolb HJ; Hausmann A; Hiddemann W; Moosmann A; Tischer J
    J Clin Virol; 2016 Sep; 82():33-40. PubMed ID: 27428881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes.
    Corrales I; Giménez E; Solano C; Amat P; de la Cámara R; Nieto J; Garcia-Noblejas A; Navarro D
    J Med Virol; 2015 Feb; 87(2):248-55. PubMed ID: 25132583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The yield of monitoring for HSV and VZV viremia in pediatric hematopoietic stem cell transplant patients.
    Patrick K; Ali M; Richardson SE; Gassas A; Egeler M; Krueger J; Lowry J; Allen U; Schechter T
    Pediatr Transplant; 2015 Sep; 19(6):640-4. PubMed ID: 26148054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-level DNAemia of parvovirus B19 (genotypes 1-3) in adult transplant recipients is not associated with anaemia.
    Plentz A; Würdinger M; Kudlich M; Modrow S
    J Clin Virol; 2013 Oct; 58(2):443-8. PubMed ID: 23916377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saliva as a source of HCMV DNA in allogeneic stem cell transplantation patients.
    Correia-Silva JF; Bruna-Romero O; Resende RG; Miranda LP; Oliveira FE; Costa FO; Xavier SG; Figueiredo-Neves SP; Almeida HC; Bittencourt H; Gomez RS
    Oral Dis; 2010 Mar; 16(2):210-6. PubMed ID: 20374507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Human herpesvirus 7 infection in patients after allogeneic hematopoietic stem cell transplantation].
    Wang LR; Dong LJ; Lu DP
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2113-6. PubMed ID: 17988530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.